DotLab, a personalized medicine company for women’s health, announced today that it has secured $10 million in Series A funding.
| SAN FRANCISCO, July 1, 2019 /PRNewswire/ -- DotLab, a personalized medicine company for women’s health, announced today that it has secured $10 million in Series A funding. CooperSurgical, a business unit of The Cooper Companies, led the financing which included individual investors from Tiger Global Management and Luxor Capital Group, as well as the law firm Wilson Sonsini Goodrich & Rosati.
DotLab combined its novel biomarkers with machine learning to pioneer the development of its non-invasive, accurate diagnostic test for endometriosis. Today’s clinical standard for endometriosis, laparoscopic surgery under general anesthesia, has not evolved in the last one hundred years. Modalities such as medical imaging are not effective at diagnosing endometriosis. Endometriosis is a chronic disease with an unknown exact prevalence, but is estimated to impact a staggering 10% of women worldwide and up to 50% in women with infertility.[1] Many women remain undiagnosed or misdiagnosed. Those who do eventually receive a diagnosis endure an average delay to diagnosis of ten years and change doctors a median of five times in the process.[2],[3] As a result of endometriosis, patients may experience significant impacts on long-term social and professional development. For example, pelvic pain symptoms may occur as early as patients’ first menstrual cycles, causing young adolescents to miss days of school. In other cases, women experience no disease symptoms until they discover that they are unable to conceive. “More than half of unexplained infertility is due to endometriosis. If the disease is diagnosed and treated prior to IVF, women will have a higher likelihood of getting pregnant,” said Dr. Hugh Taylor, Chair of Obstetrics, Gynecology and Reproductive Sciences at the Yale School of Medicine and Chief of Obstetrics and Gynecology at Yale-New Haven Hospital. DotLab partnered with researchers at Yale University to evaluate the performance of the test relative to laparoscopy in patients with and without endometriosis across multiple clinical cohorts. “The revolutionary technology behind DotLab’s endometriosis test could improve the lives of the hundreds of millions of women affected by this debilitating disease which has been under-researched and deprioritized for too long,” said DotLab CEO Heather Bowerman. “CooperSurgical brings significant operational resources and the opportunity to build upon partnerships with health systems to become a leading brand in women’s health. Our shared goal is to make DotLab’s endometriosis test widely accessible,” Bowerman continued. “DotLab plans to use its Series A financing to further clinical validation, expand market access, and continue to grow our team in the pursuit of our goals.” About DotLab About The Cooper Companies [1] D’Hooge T, Debrock S, Hill J, Meuleman C. Endometriosis and subfertility: is relationship resolved? Semin Reprod Med (2003) 21:243–54.10.1055/s-2003-41330.
SOURCE DotLab | ||
Company Codes: NYSE:COO |
View original content to download multimedia:
